The fixed dose combination of sitagliptin 50 mg and metformin 850 mg (Janumet ®), is
indicated for the treatment of type 2 diabetes mellitus in addition to diet and exercise to improve
glycemic control in patients treated with metformin alone. Methods: We report a 69-year-old man with
type 2 diabetes that developed sudden loss of eyebrows and eyelashes about 4 months after the
beginning of Janumet®.
Clinical and laboratory findings excluded the presence of systemic or skin diseases able to induce these
manifestations, while the Naranjo probability scale documented a possible association between the drug
and the adverse drug reaction.
Keywords: Adverse drug reaction, metformin, sitagliptin, type 2 diabetes mellitus.
Rights & PermissionsPrintExport